What question did this study set out to answer?

This research aims to evaluate the effectiveness of novel therapies for non-small cell lung cancer (NSCLC) with rare EGFR mutations.

June 3, 2026

Rare EGFR m NSCLC: More First-Line Options Emerge

Key Points

This research aims to evaluate the effectiveness of novel therapies for non-small cell lung cancer (NSCLC) with rare EGFR mutations.
Phase III WU-KONG28 trial assessed sunvozertinib for first-line treatment in NSCLC with EGFR exon 20 insertions.
CHRYSALIS-2 trial evaluated amivantamab combined with lazertinib for atypical EGFR mutations.
Sunvozertinib outperformed chemotherapy, improving outcomes for patients with EGFR exon 20 insertions.
Amivantamab and lazertinib showed promising initial efficacy, leading to durable overall survival for patients with atypical mutations.

Abstract

Abstract Findings from the phase III WU-KONG28 trial indicate that the next-generation tyrosine kinase inhibitor sunvozertinib, an approved later-line option for patients with non–small cell lung cancer harboring EGFR exon 20 insertions, also looks effective up front, besting chemotherapy. Meanwhile, updated CHRYSALIS-2 data point to amivantamab combined with lazertinib as a new option for patients with atypical EGFR mutations, with initial efficacy translating to durable overall survival.

Bookmark

Rare EGFR m NSCLC: More First-Line Options Emerge

Key Points

Abstract

Cite This Study